Granted Patent
B2
US 8,871,741 · App. 13/522,441 · Granted Oct 28, 2014
Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
Inventors:
Gary E. Striker (New York, NY); Helen Vlassara (New York, NY); Feng Zheng (Middle Village, NY)
Assignee:
Icahn School of Medicine at Mount Sinai
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs).
Claims (4)
1. A method of treating diabetic nephropathy, comprising:
administering to a patient in need thereof, a therapeutically effective dose of pentosan polysulfate (PPS).
2. The method of claim 1 , wherein the pentosan polysulfate (PPS) is administered as an oral formulation.
3. The method of claim 1 or 2 , wherein the pentosan polysulfate is administered at least once to the patient at fixed, escalating, decreasing doses or combinations thereof.
Assignments (3)
CONFIRMATORY LICENSE
Recorded Oct 24, 2014
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034046/0631 →
CHANGE OF NAME
Recorded Aug 5, 2014
From: MOUNT SINAI SCHOOL OF MEDICINE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 033471/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2012
From: STRIKER, GARY E.; VLASSARA, HELEN; ZHENG, FENG
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 029082/0508 →
Continuity (2)
Provisional Application
61295409
· Jan 15, 2010